C hronic beryllium disease (CBD)
3 is characterized by the accumulation of memory CD4 ϩ T lymphocytes and granulomatous inflammation in the lungs of berylliumexposed individuals (1, 2) . When stimulated with beryllium salts, a large percentage of bronchoalveolar lavage (BAL) CD4 ϩ T cells from CBD patients respond vigorously by producing proinflammatory cytokines such as IFN-␥ and TNF-␣ (3, 4) . The presence of these inflammatory cytokines leads to the recruitment of alveolar macrophages, alveolitis, and granuloma development. The regulation of this response is in part dependent on a balance between costimulatory and coinhibitory pathways. We have previously demonstrated that memory CD4 ϩ T cells in the blood of CBD patients require CD28 costimulation for proliferative and cytokine responses to beryllium (5) . Conversely, proliferation and secretion of Th1-type cytokines by effector memory T (T EM ) cells in the lung are functionally independent of CD28 costimulation, suggesting a transition within memory T cell subsets from CD28 dependence in circulating cells to CD28 independence in fully differentiated T EM cells in lung (5) . Less is known about the expression of coinhibitory molecules in CBD and other chronic inflammatory lung disorders. It has been shown that chronic exposure to conventional Ags can lead to up-regulation in the expression of negative regulators of CD4 ϩ and CD8 ϩ T cells such as programmed death-1 (PD-1) (6 -10) . However, the role of PD-1 in response to nonconventional Ags, such as beryllium, is unknown.
PD-1, a member of the CD28 family, is involved in signaling T cell death and similar to CTLA-4, negatively regulates T cell function (11, 12) . Engagement of PD-1 by its ligands, PD-L1 and PD-L2, inhibits T cell proliferation and cytokine production (13) (14) (15) . When PD-1 is engaged, Src homology phosphatase-1 and -2 block PI3K activation, interfere with glucose uptake, and alter both CD3-and CD28-mediated changes to the T cell transcriptional profile resulting in decreased T cell activation (15, 16) . Dysregulation of the PD-1 pathway has been implicated in human autoimmune diseases such as rheumatoid arthritis and type 1 diabetes (17) (18) (19) (20) (21) . PD-1-deficient mice exhibit hyperactivation of the immune system and subsequently develop autoimmune disease (13) . Recently, PD-1 has been shown to be up-regulated on virus-specific T cells during chronic disease, and its expression was directly correlated with viral Ag load (6 -9) . Taken together, these finding demonstrate that PD-1 is up-regulated on T cells that are responsive to persistent Ag to down-regulate the function of T cells which are aberrantly responding to autoantigens or to shut off a chronic inflammatory response to a pathogen. Due to the persistence of beryllium in the lung long after the cessation of exposure (22) (23) (24) , aberrant regulation of the PD-1 pathway may play an important role in the development of CBD.
With a known antigenic stimulus and an accessible target organ, CBD is an organ-specific immune-mediated disorder that provides an opportunity to investigate PD-1 expression on Ag-specific ϩ CD4 ϩ T cells from the blood of normal controls (n ϭ 13), BeS subjects (n ϭ 14), and CBD patients (n ϭ 22) and the BAL of BeS (n ϭ 8) and CBD (n ϭ 11) is shown. Median values are indicated with solid lines. Statistical significance was established using the KruskalWallis test. c, Correlation between PD-1 expression (MFI) on total BAL CD3 ϩ CD4 ϩ T cells from CBD patients (n ϭ 11) and total BAL WBC (left) and lymphocyte counts (right) is shown. 
CD4
ϩ T cells from a target organ. During chronic HIV infection, it has recently been shown that PD-1 is up-regulated on CD4
ϩ T cells to a greater extent in the lymph node (i.e., the target organ in HIV disease) compared with peripheral blood (7) . We examined the expression of PD-1 on beryllium-specific CD4 ϩ T cells from the blood and BAL of beryllium-sensitized (BeS) and CBD subjects. PD-1 expression was elevated on total CD4 ϩ T cells from the lungs of CBD subjects and was directly correlated with the severity of the CD4 ϩ T cell alveolitis. Furthermore, in the lung, PD-1 expression was most elevated on the beryllium-responsive subset of CD4 ϩ T cells. Blockade of the PD-1 pathway led to enhanced beryllium-specific CD4 ϩ T cell proliferation, indicating the functionality of this pathway. Taken together, these data demonstrate that PD-1 is up-regulated and active on beryllium-specific CD4 ϩ T cells and plays an important role in regulating the proliferative response of the beryllium-specific CD4 ϩ T cell.
Materials and Methods

Study population
Twenty-six patients with a diagnosis of CBD and 14 BeS patients were enrolled in this study. Thirteen healthy non-beryllium-exposed control subjects were also enrolled. The diagnosis of CBD was established using previously defined criteria, including a history of beryllium exposure, the presence of granulomatous inflammation on lung biopsy, and a positive proliferative response of blood and/or BAL T cells to beryllium sulfate (BeSO 4 ) in vitro (25, 26) . The diagnosis of BeS was established based on a history of beryllium exposure, a positive proliferative response of PBMC to BeSO 4 in vitro, and the absence of granulomatous inflammation or other abnormalities on lung biopsy (27, 28) . Active smokers were excluded from enrollment. Informed consent was obtained from each patient and control subject, and the protocol was approved by the Human Subject Institutional Review Boards at the University of Colorado at Denver Health Sciences Center and the National Jewish Medical and Research Center (Denver, CO). The demographics of the BeS and CBD patients are shown in Table I . No difference was seen in the age of the BeS and CBD patients enrolled in this study. The majority of both subject groups were male. Ten CBD patients were treated with oral glucocorticoids and two received oral methotrexate. No difference in beryllium-induced proliferation of blood cells was seen between BeS and CBD patients. In contrast, a significant increase in the proliferation of BAL cells from CBD patients compared with BeS subjects in response to beryllium was seen (median stimulation index, 64 (range, 1.2-230) vs 1.4 (1.0 -2.1), p Ͻ 0.0001). All clinical beryllium lymphocyte proliferation tests were performed in the Clinical Immunology Laboratory (National Jewish Medical and Research Center). CBD subjects had a statistically significant increase in the percentage of BAL lymphocytes (median, 29%; range, 6 -84%) compared with BeS patients (median, 6.7%; range, 2.5-29%; p Ͻ 0.0001).
Preparation of peripheral blood and BAL cells and beryllium-induced cytokine production
PBMCs were isolated from heparinized blood by Ficoll-Hypaque density gradient separation, and BAL was performed as previously described (29, 30) . PBMCs (2.5-5 ϫ 10 6 ) were resuspended in RPMI 1640 plus 10% heat-inactivated human serum (Gemini Bio-Products), placed in 12-ϫ 75-mm culture tubes, and incubated overnight at 37°C in a humidified 5% CO 2 atmosphere. Following the overnight incubation, 3 g/ml anti-CD28 and -CD49d mAbs (BD Biosciences) were added, and the cells were stimulated under the following conditions: 100 M BeSO 4 (Brush Wellman), 10 ng/ml staphylococcal enterotoxin B (SEB) (Toxin Technologies), or medium alone. The cultures were incubated at a 5°slant at 37°C in a humidified 5% CO 2 atmosphere for 6 h with brefeldin A (BD Biosciences) added after 1 h.
Immunofluorescence staining of stimulated CD4
ϩ T cells and monocytes Stimulated PBMCs were washed and stained with anti-CD4 (allophycocyanin-Cy7; BD Biosciences), anti-CD3 (PE-Texas Red; Beckman Coulter), anti-CD8 (Alexa Fluor 405; Caltag Laboratories), and anti-CD279 (PD-1) (FITC; BD Biosciences) mAbs for 30 min at 4°C. Cells were washed with PBS containing 1% BSA, fixed, permeabilized, and stained with anti-IFN-␥ (PE-Cy7; BD Biosciences) and anti-IL-2 (allophycocyanin; Caltag Laboratories) mAbs for 30 min at 4°C. Fluorescence minus one and isotype controls were used in all staining. In some experiments, the cells were also stained with anti-CD27, -CCR7, and -CD45RA mAbs (all obtained from BD Biosciences). PBMCs or BAL cells were stained with anti-CD14-FITC (BD Biosciences) and PE-labeled anti-PD-L1 or -PD-L2 mAbs (both obtained from BD Biosciences). Cells were first incubated with FcR-blocking reagent (Miltenyi Biotec) to reduce nonspecific staining.
Proliferation assay
Proliferation assays were performed using PBMCs and BAL cells (2 ϫ 10 6 cells/well) labeled with 2.0 M CFSE (Molecular Probes) (31, 32) . The CFSE-labeled cells were cultured at 37°C for 5 days in a humidified 5% CO 2 atmosphere in RPMI 1640 supplemented with 10% heat-inactivated human serum, 20 mM HEPES, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glutamine (all from Invitrogen Life Technologies) with the addition of either medium, 10 g/ml platebound anti-CD3, or 100 M BeSO 4 . PD-L1 and/or PD-L2 mAbs (1 g/ml; eBioscience) were added to the cultures to block PD-1 ligation. Cells were ϩ T cell pool is depicted in each quadrant. PD-1 expression (MFI) for each memory subset is shown to the right of the density plots. b, PD-1 expression on T CM (CCR7 ϩ CD45RA Ϫ ) and T EM (CCR7 Ϫ CD45RA Ϫ ) cells from the PBL (n ϭ 13) and BAL (n ϭ 6) of CBD patients is shown. The median PD-1 MFI on CD4 ϩ T cells expressing each maturation phenotype is indicated as a solid line. c, The percentage of CD3 ϩ CD4 ϩ T cells in the PBL (n ϭ 9) and BAL (n ϭ 7) expressing PD-1 in relation to CD27 is shown. Median values are indicated with solid lines. Statistical comparisons were made using the Mann-Whitney U test. stained with mAbs directed against CD3-PE (BD Biosciences), CD4-allophycocyanin (Caltag Laboratories), and CD8-PerCP (BD Biosciences). Cells were washed and resuspended in 1% formaldehyde.
Flow cytometry
Cells were analyzed using a FACSAria flow cytometer (BD Immunocytometry Systems). The number of events collected ranged between 1 and 3 million. Electronic compensation was performed with Ab capture beads (BD Biosciences) stained separately with individual mAbs used in the test samples. The data files were analyzed using Diva software (BD Biosciences). Lymphocytes were gated based on their forward and side scatter profile. CD3 ϩ cells were selected, and the expression of CD4 and CD8 was analyzed in a bivariate dot plot. Because PD-1 expression was not bimodal, expression levels on CD4 ϩ T cells were determined by subtracting the mean fluorescence intensity (MFI) of the fluorescence minus one control from the PD-1 MFI on the population of interest. Biexponential scaling was used in all dot plots. Because the frequency of beryllium-specific CD4 ϩ T cells in blood tends to be low, we only examined the expression of PD-1 on cytokine-producing cells with frequencies Ն0.04% to ensure an adequate number of events for analysis as previously described (31) (32) (33) . The CFSE-blocking experiments were acquired using a FACSCalibur flow cytometer (BD Immunocytometry Systems), and CellQuest Pro software was used to analyze the data.
Statistical analysis
The Mann-Whitney U test and the Kruskal-Wallis ANOVA were used to determine significance of differences between subject groups. A Spearman correlation was performed to analyze the association between PD-1 expression on BAL CD4
ϩ T cells and continuous variables of CBD. A p value of Ͻ0.05 was considered statistically significant.
Results
PD-1 expression is elevated on total BAL CD4 ϩ T cells from CBD subjects
Because the expression of PD-1 is up-regulated on T cells in response to persistent viral Ag exposure, we initially analyzed PD-1 expression on blood and BAL CD4 ϩ T cells from patients with CBD, a disease characterized by persistent exposure to a nonconventional T cell Ag. Freshly isolated PBMCs and BAL cells were obtained from CBD patients (n ϭ 22 PBL, 11 BAL), BeS subjects (n ϭ 14 PBL, 8 BAL), and normal control subjects (n ϭ 13 PBL), and the MFI of PD-1 expression on total CD3 ϩ CD4 ϩ T cells was determined by immunofluorescence staining and cytofluorographic analysis. Representative histograms of PD-1 expression on total CD3 ϩ CD4 ϩ T cells from the peripheral blood and BAL of a CBD subject are shown in Fig. 1a . PD-1 expression (MFI) was significantly higher on BAL CD4 ϩ T cells (median, 1508; range, 308 -4384) from CBD subjects compared with either blood CD4 ϩ T cells (588, range 99 -1561) from the same disease cohort or BAL CD4 ϩ T cells (755; range, 332-1073) from BeS subjects ( p Ͻ 0.01 and p Ͻ 0.001, respectively) (Fig. 1b) . Although not statistically significant, PD-1 expression trended higher on total CD4 ϩ T cells from the blood of CBD patients (median, 588; range, 99 -1561) compared with the expression on blood CD4
ϩ T cells from BeS subjects (median, 365; range, 193-635) and normal control subjects (median, 302; range, 110 -386). Based on the observation that PD-1 expression on T cells from subjects with chronic viral infections was associated with disease severity (6, 7, 9), we correlated PD-1 expression on BAL CD4 ϩ T cells from CBD patients with total BAL white blood cell (WBC) and lymphocyte counts (Fig. 1c) . Significant positive correlations were seen for both total BAL WBC count (r ϭ 0.70; p ϭ 0.02) and lymphocyte count (r ϭ 0.66; p ϭ 0.03). No correlation was observed, however, between PD-1 expression on BAL CD4
ϩ T cells and total BAL macrophage count (r ϭ Ϫ0.34; p ϭ 0.29) (data not shown). Thus, the severity of the CD4 ϩ T cell alveolitis appears to be closely tied to PD-1 expression on CD4 ϩ T cells in the BAL.
PD-1 expression is higher on less differentiated T cell subsets in the lung
Due to the association of PD-1 expression with T cell exhaustion, we determined whether its expression on CD4 ϩ T cells was correlated with the expression of other memory T cell markers. Using CCR7 and CD45RA to identify CD4 ϩ memory T cell subsets, we evaluated PD-1 expression on central memory T (T CM ) and T EM cells in blood and BAL (Fig. 2) . As expected, the median PD-1 expression (MFI) on blood CD4
ϩ T cells was higher on T EM cells (962; range, 597-1371) compared with T CM cells (582; range, 321-863; p ϭ 0.002). Conversely, BAL CD4
ϩ T CM cells expressed higher levels of PD-1 (2541; range, 1925-6980) than the T EM cell subset (1062; range, 676 -1810; p ϭ 0.002) (Fig. 2, a and  b) . Using CD27, another marker used to differentiate T CM from T EM cells, we again observed the same trend with the CD4 ϩ CD27 ϩ T cell subset containing a higher percentage of PD-1-expressing cells in the lung ( p ϭ 0.01) while CD4 ϩ CD27 Ϫ T cells contained a greater percentage of PD-1-expressing CD4 ϩ T cells in the blood ( p ϭ 0.06) (Fig. 2c) . These findings suggest that PD-1-expressing CD4 ϩ T cells in the circulating pool represent a subset of the differentiated T EM cell population while in the lung these cells are predominately found in the T CM cell subset.
PD-1 expression is up-regulated on beryllium-specific CD4
ϩ T cells
To determine whether PD-1 expression is up-regulated on beryllium-specific CD4 ϩ T cells, we measured the levels of PD-1 on beryllium-specific and SEB-reactive IFN-␥-producing T cells in CBD subjects. IFN-␥-producing T cells were initially analyzed because we had previously shown that beryllium-specific CD4 ϩ T cells in both blood and BAL were skewed toward poorly proliferating, IFN-␥-producing T EM cells (32) . Polychromatic flow cytometry was used to measure PD-1 expression on Ag-specific
cells. Representative density plots for blood and BAL CD4
ϩ T cells stimulated with either medium, BeSO 4 , or SEB are shown in Fig. 3a . IFN-␥-secreting, berylliumspecific CD4 ϩ T cells from the BAL expressed significantly higher levels of PD-1 than either total CD3 ϩ CD4 ϩ T cells or berylliumreactive CD4 ϩ T cells in blood (Fig. 3) . The median PD-1 expression on IFN-␥ ϩ , beryllium-specific CD4 ϩ T cells from the BAL was 2009 (range, 526 -5308) compared with 1005 (median; range, 427-2859; p ϭ 0.027) for IFN-␥ ϩ , beryllium-reactive CD4 ϩ T cells in blood (Fig. 3b, left) . Although not statistically significant, PD-1 expression (MFI) on beryllium-specific, IFN-␥ ϩ , CD4 ϩ T cells in BAL was also higher compared with PD-1 expression on SEB-reactive CD4 ϩ T cells (median, 1665; range, 264 -3962; p ϭ 0.15) in the same compartment. This is not altogether surprising because we have previously shown that the beryllium-reactive CD4 ϩ T cells that are recruited to the lung in CBD express TCR ␤-chain V regions (V␤) that are responsive to SEB (e.g., V␤3 and V␤17) (29) . In addition to MFI, the data were also analyzed as percent positive and the same trends and statistical significance were seen (data not shown).
No difference in PD-1 expression on IFN-␥-only and IFN-␥/IL-2-secreting, beryllium-responsive CD4
It is widely accepted that IFN-␥-producing CD4 ϩ T cells are more differentiated than CD4 ϩ T cells that retain the ability to secrete IL-2 (34). However, it is less clear whether differences exist between cells that produce only IFN-␥ and those that continue to express IL-2 in addition to IFN-␥. To determine whether the expression of PD-1 differed during the various stages of CD4 ϩ T cell differentiation, we measured PD-1 on BeSO 4 -responsive CD4 ϩ T cells that produced either IFN-␥ alone, IFN-␥ and IL-2, or no cytokine from the blood and BAL of CBD subjects. Fig. 4a shows representative histograms of PD-1 expression on cytokine-producing CD4 ϩ T cells from the blood and BAL. Overall, the level of PD-1 expressed on beryllium-specific CD4 ϩ T cells in the BAL was higher than on beryllium-specific cells in blood. However, no significant difference between PD-1 expression on IFN-␥-only and IFN-␥/IL-2-secreting CD4 ϩ T cells was observed, irrespective of the location of the beryllium-responsive T cell. For example, the median PD-1 expression (MFI) on beryllium-specific, IFN-␥-only producing CD4 ϩ T cells in blood was 1120 (range, 464 -3079) compared with 892 (range, 391-2639) on IFN-␥/IL-2-producing cells and 458 (range, 261-1611) on cells which do not express either IFN-␥ or IL-2 ( p Ͼ 0.05) (Fig. 4b) . Similar findings were seen for IFN-␥-only and IFN-␥/IL-2-expressing CD4 ϩ T cells in the BAL in response to BeSO 4 .
Increased expression of PD-L1 and PD-L2 in the lung
Suppression of PD-1-expressing T cells requires that the PD-1 ligands (PD-L1 and PD-L2) are expressed on APCs. To examine this, PD ligand expression was measured by flow cytometry on CD14 ϩ monocyte/macrophages in PBMCs and BAL cells from BeS, CBD, and normal control subjects. There was no difference between groups in the expression of PD-L1 and PD-L2 on CD14 ϩ cells from blood (Fig. 5) . The median PD-L1 expression (MFI) on CD14 ϩ cells from the peripheral blood of BeS, CBD, and normal subjects was 6.6, 9.4, and 13, respectively (Fig. 5a) . The median PD-L2 expression (MFI) on CD14 ϩ cells from blood in BeS, CBD, and normal subjects was 2.5, 2.6, and 7, respectively (Fig.  5b) APCs in the BAL of BeS and CBD patients have significantly higher levels of PD-1 ligands than those in the blood, suggesting that the PD-1 pathway is active and up-regulated in the BAL and not specific for CD14 ϩ cells in the lung of CBD patients.
Blocking the PD-1 pathway enhances beryllium-specific CD4 ϩ T cell proliferation
To demonstrate that the PD-1 pathway is functional in CBD, we blocked PD-1 interaction with its ligands using mAbs directed against PD-L1 and PD-L2. PBMCs from 14 CBD patients were labeled with CFSE, and proliferation was measured as the percentage of CFSE low CD3 ϩ CD4 ϩ T cells after 7 days of stimulation with 100 M BeSO 4 . Representative density plots from a CBD subject showed enhanced BeSO 4 -specific CD4 ϩ T cell proliferation by blocking the PD-1 pathway using anti-PD-L1, anti-PD-L2, and a combination of both mAbs (Fig. 6a) . All 14 subjects exhibited an increase in beryllium-specific CD4 ϩ T cell proliferation upon blockade with a mAb directed against PD-L1 alone ( p ϭ 0.006) (Fig. 6b, left panel) . Blockade with PD-L2 mAbs was not as effective with only 8 of 14 subjects demonstrating increased proliferation compared with BeSO 4 alone ( p ϭ 0.7) (Fig. 6b, center  panel) . Blocking the pathway with the addition of both anti-PD-L1/L2 mAbs also resulted in a significant increase in berylliumspecific CD4
ϩ T cell proliferation ( p ϭ 0.01) (Fig. 6b, right  panel) . The greatest enhancement of proliferation occurred when the blocking Ab was used at a concentration of 1 g/ml (titration range 0.1-5 g/ml; data not shown). Thus, the PD-1 pathway is indeed functional in CBD, and blockade of that pathway reinvigorates exhausted beryllium-specific CD4 ϩ T EM cells. To determine whether the reduced lymphocyte proliferation seen in certain CBD subjects was related to the high expression of PD-1, we correlated PD-1 expression on beryllium-responsive, IFN-␥-expressing CD4 ϩ T cells with the ability of CD4 ϩ T cells from nine subjects to proliferate after BeSO 4 exposure in culture (Fig. 6c) . A significant inverse correlation was seen (r ϭ Ϫ0.72; p ϭ 0.04), further emphasizing the importance of the PD-1 pathway in controlling beryllium-induced T cell proliferation.
Discussion
Aberrant proliferation and cytokine production by CD4 ϩ T cells in the lungs of subjects exposed to beryllium is central to the immunopathogenesis of beryllium-induced disease. Determining how beryllium-specific CD4 ϩ T cells in the lung are regulated represents an important area for understanding the mechanisms responsible for the development and progression of lung fibrosis. We have previously shown that beryllium-specific memory CD4 ϩ T cells in blood remain dependent on CD28 engagement for optimal T cell activation while lung CD4 ϩ T cells no longer require CD28 costimulation for either proliferation or Th1-type cytokine secretion (5) . Another member of the CD28 family, PD-1, is a negative regulator of T cell function and is up-regulated on circulating T cells persistently exposed to Ag. CBD represents an important model of persistent Ag exposure and is characterized by the accumulation of large numbers of beryllium-specific CD4 ϩ T cells in the lung (1-3) . The present study is the first to demonstrate that PD-1 is up-regulated on lung CD4 ϩ T cells during an inflammatory response and that the PD-1 pathway in the lung is indeed functional. In addition, we demonstrate that persistent exposure to a nonconventional Ag, such as beryllium, leads to increased expression of PD-1 on Ag-specific CD4 ϩ T cells. These findings provide at least a partial explanation for the reduction in berylliuminduced lymphoproliferation seen in certain individuals with CBD despite the presence of Th1-type, cytokine-expressing, berylliumspecific CD4 ϩ T cells. T cell regulation is important for initiating protective T cell responses to foreign Ags as well as to "switch off" harmful or aberrant responses to either self or persistent Ags. We have previously demonstrated that a large percentage of lung CD4 ϩ T cells from CBD patients had lost CD28 expression and that the loss of CD28 extended to cells that were not responsive to beryllium (5) . This is in contrast to the presence of PD-1 on the majority of IFN-␥-expressing, beryllium-responsive CD4 ϩ T cells in the BAL. These findings suggest that the up-regulation of PD-1 expression on beryllium-responsive CD4 ϩ T cells in the lung was most likely related to the persistence of beryllium in the target organ. Because these cells no longer require a second signal from professional APCs for optimal T cell activation, it is possible that they could respond in an uncontrolled manner to persistent Ag exposure, resulting in exuberant tissue damage. Thus, in the presence of persistent Ags, such as beryllium, the up-regulation of coinhibitory molecules may represent a vital step in controlling the adaptive immune response.
Following activation, T cells express coinhibitory molecules such as PD-1, CTLA-4, or B and T lymphocyte attenuator which function to down-regulate the immune response (35) . We have previously shown that CTLA-4 is expressed following the activation of beryllium-specific CD4 ϩ T cells from the lungs of CBD subjects (5) . In the present study, we found that PD-1 expression is up-regulated on CD4 ϩ T cells from the BAL of subjects with CBD and closely correlated with the severity of the CD4 ϩ T cell alveolitis. An important unanswered question is whether the severity of the alveolitis, and thus the up-regulation of PD-1 on CD4 ϩ T cells, is tied to a greater beryllium burden in the lung. Blocking of the interaction between PD-1 and its ligands enhanced the proliferative capacity of beryllium-specific CD4 ϩ T cells suggesting that this inhibitory pathway is active. The ligands for PD-1 are highly expressed on CD14 ϩ alveolar macrophages, but not on blood monocytes, and yet BAL CD4 ϩ T cells from CBD patients still produce copious amounts of Th1-type cytokines after beryllium recognition. In addition, there are some CBD subjects who possess large numbers of beryllium-specific CD4 ϩ T cells in the lung (e.g., up to 20% of BAL CD4 ϩ T cells from CBD patients express IFN-␥ and TNF-␣ after beryllium exposure in culture) which lack a proliferative potential, suggesting that, at least in some subjects, the PD-1 pathway may control the proliferative capacity of these pathogenic effector T cells. At the present time, it remains unclear whether the PD-1 pathway affects just proliferation or whether cytokine production is also affected. However, Petrovas et al. (36) recently showed that the engagement of PD-1 during Ag stimulation had no effect on the ability of HIV-or CMV-specific CD8 ϩ T cells to produce either IFN-␥, TNF-␣, or IL-2.
The lung represents a unique environment that is constantly exposed to inhaled Ags. For this reason, a mechanism to down-regulate uncontrolled T cell responses in the lung must be in place. Although PD-1 expression was 2-fold higher in the lungs of CBD compared with BeS subjects, its expression in both cohorts was significantly higher than in blood suggesting that the PD-1 pathway may play a role in the down-regulation of T cell responses in the lung. To date, most studies have examined PD-1 expression on CD4 ϩ T cells in blood. Thus, little information exists on the expression of PD-1 on Ag-specific CD4 ϩ T cells in a target organ. We have recently shown that PD-1 expression on CD4 ϩ T cells in the lymph nodes of subjects with chronic HIV infection was significantly higher than on cells from blood (7) . Although this is in part a consequence of persistently high levels of viral Ag, it may also be that PD-1 expression in target organs is higher than in the bloodstream because of the activated state of the cells. In the present study, we observed increased PD-1 expression on CD4 ϩ T cells in the lung as well as increased expression of its ligands on alveolar macrophages. The expression of PD-L1 and PD-L2 was not only high in the lung of CBD patients, but also in the lung of BeS subjects suggesting that these receptors may be constitutively expressed on alveolar macrophages in the lung. The suppressive effects of alveolar macrophages on T cell functions has been welldocumented (37) (38) (39) , and our data suggest that this could be in part due to the high level of PD-1 ligand expression.
In addition to T cell exhaustion, PD-1 plays a role in the differentiation of T cells. In HIV disease, we have previously demonstrated that PD-1 expression is greater on more differentiated IFN-␥-producing CD4 ϩ T cells than less differentiated cells that only produced IL-2 (7). For that reason, we initially hypothesized that CD4
ϩ T EM cells in the lung, which represents the major CD4 ϩ T cell subset in the BAL (3), would also express the highest levels of PD-1. However, PD-1 was actually expressed at the highest levels on BAL CD4
ϩ T CM cells. Investigating CD8 ϩ T cells from normal and HIV-infected individuals, Sauce et al. (40) showed that PD-1 expression was highest on cells with an early to intermediate stage of differentiation, with decreased expression of PD-1 on more differentiated T cell subsets. On influenza-specific CD8 ϩ T cells in blood, PD-1 was also expressed on less differentiated T cell subsets (41) . These data suggest that there is a direct link between the level of differentiation and the expression of PD-1 on CD8 ϩ T cells. Based on these recent studies and our present findings, we hypothesize that the immune system is attempting to down-regulate the function of these recently recruited lung CD4 ϩ T CM cells to potentially prevent their differentiation into pathogenic T EM cells. Limiting the capacity of T CM cells to divide and differentiate into the T EM cells which produce the inflammatory cytokines could lead to decreased recruitment of alveolar macrophages, alveolitis, and granuloma development.
Due to the persistent presence of beryllium in the lung (24), CBD is not curable and requires continuous treatment once therapy is initiated. Although corticosteroid treatment provides symptomatic relief, it does not result in a significant drop in the number of CD4 ϩ T cells in the lung or the number of circulating berylliumspecific CD4 ϩ T cells (29, 42) . This study clearly demonstrates that PD-1 expression on beryllium-specific CD4 ϩ T cells is upregulated and that the pathway is active. Although alveolitis persists, it is likely that the PD-1 pathway is leading to some decrease in beryllium-specific CD4 ϩ T cell function and severity of disease. Engagement of the PD-1 receptor with either a stimulatory mAb or soluble PD-L1/L2 could lead to additional functional down-regulation of beryllium-specific CD4 ϩ T cells in the lung. The development of targeted immunotherapy that would specifically downregulate the function of pathogenic T cells, not only for CBD, but for other inflammatory lung diseases where Ag persists and T cell regulation is lost, would represent an important advance. A PD-1-based immunotherapeutic treatment may be superior to systemic corticosteroids, which reduce the function of all T cells, because it would directly target Ag-specific CD4 ϩ T cells which are responsible for the production of proinflammatory cytokines such as IFN-␥ and TNF-␣.
In summary, the present study shows, for the first time, that PD-1 expression is significantly up-regulated on Ag-specific CD4 ϩ T cells in the lungs of subjects with chronic pulmonary inflammation. Although we have demonstrated that the PD-1 pathway is active by showing increased beryllium-specific CD4 ϩ T cell proliferation after blocking PD-1 interaction with its ligands, its expression is directly correlated with the severity of the CD4 ϩ T cell alveolitis, suggesting that this pathway alone is not sufficient to completely down-regulate T cell function for control of disease. A better understanding of the role of PD-1 in CBD and other pulmonary inflammatory diseases could provide important insight into the mechanism of disease progression and the development of lung fibrosis.
